AGNPF - Algernon posts full Phase 2 data set for lung disease candidate

• Canadian biopharma company Algernon Pharmaceuticals Inc. ( OTCQB:AGNPF ) announced the complete data set from its Phase 2a study for lead candidate NP-120 (“Ifenprodil”) in idiopathic pulmonary fibrosis (“IPF”) and chronic cough.
• Announcing topline data from the 20-patient study, Algernon ( OTCQB:AGNPF ) said in July that the trial’s primary cough main goal did not achieve statistical significance compared to an anticipated placebo effect of 25%.
• However, the secondary endpoint of actual changes (reduction) in cough counts reached statistical significance.
• For IPF, the co-primary endpoint of preservation of lung function measured using forced vital capacity (“FVC”) had achieved statistical significance.
• Full data includes additional secondary goals of efficacy, including both objective measures of lung function and patient-reported outcomes.
• The company said that the experimental therapy was well tolerated, with an average compliance rate of more than 90%, and there were no new safety concerns.
• Algernon ( OTCQB:AGNPF ) plans to share data with the FDA seeking an Orphan Drug Designation, Breakthrough Therapy designation, and a submission of a pre-IND application for a Phase 2b trial.
• Read more on the topline data from the study.

For further details see: